Clinical trials: Breast Cancer Stage I
Cancer
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
The purpose of this study is to determine whether ETBX-021 is safe and effective in the treatment of unresectable locally advanced or metastatic HER2-low-expressing breast cancer.
- Trial name
- NCT02751528
- Testing
- ETBX-021
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- NantBioScience, Inc.
Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative…
- Trial name
- NCT07117214
- Testing
- [68Ga]Ga-DWJ155
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors Amenable to Anthracycline Therapy, Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy
L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Prospective, open-label, non randomized, dose escalation study that will be conducted in sequential cohorts of patients.
- Trial name
- NCT02076620
- Testing
- L19TNFα, Doxorubicin
- Where
- 2 sites in Germany, Italy
- Volunteers
- 29 people
- Sponsor
- Philogen S.p.A.
Breast Cancer
MRI-Guided Ultrasound Energy in Treating Patients With Stage I, Stage II, or Stage IIIA Breast Cancer
RATIONALE: Imaging procedures, such as MRI, may allow the doctor to better detect the tumor. Highly focused ultrasound energy may be able to kill tumor cells by heating the breast tumor cells without affecting the surrounding…
- Trial name
- NCT00008437
- Testing
- high-intensity focused ultrasound ablation
- Where
- 2 sites in United States, Canada
- Sponsor
- InSightec
Brain Metastases, Lung Cancer
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab.
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma
- Trial name
- NCT01386580
- Testing
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 84 people
- Sponsor
- BBB-Therapeutics B.V.
Breast Cancer
Breast Cancer Index (BCI) Registry
The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in…
- Trial name
- NCT04875351
- Testing
- Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test
- Where
- 105 sites in United States
- Volunteers
- 3,465 people
- Sponsor
- Biotheranostics, Inc.
Neoplasms, Breast
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).
- Trial name
- NCT00148902
- Testing
- lapatinib, docetaxel
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of GRN163L in combination with paclitaxel and bevacizumab in patients with locally recurrent or metastatic breast cancer (MBC)
- Trial name
- NCT00732056
- Testing
- GRN163L
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Geron Corporation
Metastatic Breast Cancer
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
This study is a Phase I/II trial of a novel Indibulin dosing schedule for the treatment of metastatic breast cancer. Eligible patients will have measurable or non-measurable, metastatic or unresectable, locally advanced breast…
- Trial name
- NCT01113970
- Testing
- Indibulin
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Alaunos Therapeutics
Metastatic Breast Cancer
A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
This is a phase I, multicenter, open-label, dose-escalation study of single-agent trastuzumab-MCC-DM1 administered by intravenous (IV) infusion in patients with HER2-positive metastatic breast cancer (MBC) who have previously…
- Trial name
- NCT00932373
- Testing
- trastuzumab-MCC-DM1
- Volunteers
- 54 people
- Sponsor
- Genentech, Inc.
Breast Cancer
Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters
RATIONALE: Collecting blood samples and health information from patients with invasive breast cancer and from their brothers and sisters over time may help the study of cancer in the future.
- Trial name
- NCT00445562
- Testing
- biologic sample preservation procedure, informational intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GenBasix Incorporated
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
The purpose of this study is determine if the triplet combination of ribociclib, everolimus and exemastane is safe and effective in the treatment of locally advanced/metastatic breast cancer following treatment with a CDK 4/6…
- Trial name
- TRINITI-1 (NCT02732119)
- Testing
- Ribociclib, Everolimus, Exemestane
- Where
- 25 sites in United States
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Study of SKB103 in HER2-negative Breast Cancer
This is a Phase I/II clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced (locally advanced, recurrent, or metastatic) HER2-negative breast cancer.
- Trial name
- NCT07774624
- Testing
- SKB103 monotherapy
- Volunteers
- 140 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Breast Cancer
Koning Breast Computed Tomography Guided Biopsy
The primary aim of this study is to show that the accuracy of Koning Breast CT-guided biopsy is at least equivalent to that of stereotactic-guided biopsy.
- Trial name
- NCT01750320
- Testing
- Koning Breast CT-guided Biopsy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Koning Corporation
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Colorectal Cancer Metastatic, Triple Negative Breast Cancer
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and…
- Conditions
- Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03775850
- Testing
- EDP1503, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Evelo Biosciences, Inc.
Metastatic Breast Cancer
ABI-008 Trial in Patients With Metastatic Breast Cancer
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given…
- Trial name
- NCT00531271
- Testing
- ABI-008 (nab-docetaxel)
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Celgene
Malignant Solid Tumors, Lymphoma
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
- Conditions
- Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03205176
- Testing
- AZD5153, Olaparib
- Where
- 4 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca